Sera Prognostics(US:SERA)2025-03-20 04:49Financial Data and Key Metrics Changes - Net revenue for Q4 2024 was $24,000, down from $41,000 in Q4 2023 [20] - Total operating expenses for Q4 2024 were $9,400,000, up 6% from $8,900,000 in the same period last year [20] - Net loss for the quarter was $8,600,000 compared to $7,900,000 for the same period a year ago [21] - Cash, cash equivalents, and available for sale securities as of 12/31/2024 were approximately $68,200,000 [21] - Gross cash expense for 2024 was about $28,600,000, below the expectation of less than $30,000,000 [22] Business Line Data and Key Metrics Changes - Research and development expenses decreased to $3,100,000 from $3,900,000 in Q4 2023, primarily due to reduced expenses related to the PRIME study [21] - Selling, general, and administrative expenses increased to $6,300,000 from $5,000,000 in Q4 2023, driven by spending on commercial activities [21] Market Data and Key Metrics Changes - The company is focusing on states with high preterm birth rates, such as Nevada and Louisiana, which have nearly 50% higher rates than the national average [16] - Medicaid covers approximately 43% of births in the U.S., representing a significant opportunity for the company to reduce costs for Medicaid administrators [33] Company Strategy and Development Direction - The company aims to expand its commercialization efforts and grow adoption of its preterm test, leveraging recent PRIME study results [5][12] - Plans include building a strong sales organization and increasing awareness through targeted education campaigns [50] - The company is also exploring international expansion and developing an immunoassay version of its preterm tests for the European market [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for Medicaid to adopt their test more quickly due to the current focus on cost reduction and clinical breakthroughs [34] - The company anticipates a pivotal year in 2025 for engagement with key stakeholders and adoption of their preterm test [23] - Management highlighted the importance of generating real-world evidence to support the adoption of their test and treat strategy [29] Other Important Information - The company successfully raised $57,500,000 through a public follow-on offering to expand commercial operations [21] - The PRIME study showed a 25% reduction in neonatal mortality and morbidity index and an 18% reduction in neonatal length of hospital stay [8] - The company is targeting the launch of its time to birth product in the second half of 2025, priced around $150 [54][55] Q&A Session Summary Question: Can you elaborate on the three tenants of your plan to get into guidelines? - Management discussed plans for publications from the PRIME dataset and the importance of generating real-world evidence to support adoption [27][29][30] Question: What are your plans regarding Medicaid and the opportunity ahead of guidelines? - Management emphasized the significant opportunity with Medicaid, highlighting the potential for quicker adoption due to cost-saving benefits [33][34] Question: How do you view the importance of ACOG and SMFM in the guidelines process? - Management noted that both societies are important and are likely to work together on guidelines, with an emphasis on generating more evidence [37][40] Question: What is the cash runway based on current operating plans? - Management indicated a cash runway into 2028, with operating expenses expected to be between $30,000,000 and $35,000,000 [43] Question: What are the commercial investments planned for 2025? - Management outlined plans to build a sales organization and increase awareness through targeted campaigns [50]